Text Size

Endometrial Cancer Nomogram : Disclaimer

The prediction tools, also known as prognostic nomograms, located on the MSKCC Web site are for general health information only. The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem.

Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. Questions should be addressed to your own physician or other healthcare provider.

MSKCC makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSKCC does not assume any risk whatsoever for your use of the prediction tools or the information contained herein. Health related information changes frequently and therefore information contained in the prediction tools may be outdated, incomplete or incorrect.

Use of the prediction tools does not create an express or implied physician-patient relationship. MSKCC does not endorse or claim validity for the prediction tools found on the MSKCC Web site. The activities and products of MSKCC and its developers and agents (collectively MSKCC) are not endorsed by our past, present, or future employers. MSKCC does not record specific prediction tool user information and does not contact users of the prediction tools.

You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. In using the prediction tools, you agree that neither MSKCC nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools.

I accept all of the above terms by clicking here or by any further use of this service.
I do not accept all of the above terms.

Endometrial Cancer Nomogram

This tool predicts the chance of overall survival following primary therapy for endometrial cancer. This tool may be used by clinicians in assessing risk when deciding on follow-up strategies.

CalculateClearEnter Your Information

Age at diagnosis.
(20 to 100 yrs)
Enter the number of lymph nodes that were found to be negative (not cancerous) from the pathology report. Note: Please include the number of negative nodes even if other nodes are positive.
(0 to 100)
Surgical 1988 FIGO Stage
Select "grade 3" for the following tumor subtypes: serous, clear cell, and carcinosarcoma. FIGO Grade.
Enter the specific subtype of endometrial cancer assigned after pathology analysis.

Learn More About Your Results

Probability of overall survival

This tool predicts the chance of overall survival following primary therapy for endometrial cancer. This tool may be used by clinicians in assessing risk when deciding on follow-up strategies. This tool incorporates other individualized patient variables beyond FIGO stage to more accurately predict outcome.

Supporting Publications

Bendifallah S, Canlorbe G, Raimond E, Bazire L, Huguet F, Graesslin O, Rouzier R, Darai E, Ballester M. An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer. 2013 Sep 17;109(6):1498-503. doi: 10.1038/bjc.2013.500. Epub 2013 Aug 29.
Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, Concin N, Leitao MM Jr, Barakat RR, Abu-Rustum NR, Iasonos A. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol. 2012 Jun;125(3):526-30. doi: 10.1016/j.ygyno.2012.03.030. Epub 2012 Mar 23.
Koskas M, Bendifallah S, Luton D, Darai E, Rouzier R. Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecol Oncol. 2011 Nov;123(2):214-20. doi: 10.1016/j.ygyno.2011.08.006. Epub 2011 Sep 8.
Abu-Rustum, NR, Zhou Q, Gomez, JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, Iasonos, A. Gynecol Oncol. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. 2010 Mar;116(3):399-403.